This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / OKYO Pharma Transitions ATM Facility...
Business ATM facility transition

OKYO Pharma Transitions ATM Facility to Leerink Partners

Analysis based on 9 articles · First reported Feb 11, 2026 · Last updated Feb 11, 2026

Sentiment
10
Attention
2
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market impact is generally positive for OKYO Pharma as it secures a new partner for capital raising, enhancing its financial flexibility. Leerink Partners benefits from a new mandate, while B. Riley Financial===B. Riley Securities experiences a minor negative impact from losing the facility.

Biotechnology Financial services
Event Summary

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, announced the transition of its At-The-Market (ATM) equity offering facility to Leerink Partners LLC. Leerink Partners will now serve as the exclusive sales agent, replacing B. Riley Financial===B. Riley Securities Inc. This strategic move aims to provide OKYO Pharma with efficient access to capital markets, allowing the sale of common shares at prevailing market prices to support ongoing clinical development, including its lead candidate urcosimod for neuropathic corneal pain, and other corporate objectives. Kiran Shah, CFO of OKYO Pharma, highlighted Leerink Partners' expertise in the biotech sector as a key factor in this partnership. Leerink Partners will receive a 3.0% commission on gross proceeds from any shares sold under the program, which will be conducted in compliance with United States===United States Securities and Exchange Commission filings.

Key Actions
100 OKYO Pharma transitioned ATM equity offering facility Leerink Partners
95 Leerink Partners became exclusive sales agent OKYO Pharma
90 OKYO Pharma replaced ATM facility sales agent B. Riley Financial===B. Riley Securities
Entities Involved
stock
OKYO Pharma
OKYO Pharma transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners LLC, replacing B. Riley Financial===B. Riley Securities Inc. This move provides OKYO Pharma with enhanced financial flexibility to raise capital opportunistically for its clinical development and corporate objectives.
Importance 100 Sentiment 20
priv
Leerink Partners
Leerink Partners LLC became the exclusive sales agent for OKYO Pharma's ATM facility, replacing B. Riley Financial===B. Riley Securities Inc. This partnership is expected to leverage Leerink Partners' expertise in the biotech sector and investor relationships, earning them a 3.0% commission on gross proceeds from shares sold.
Importance 90 Sentiment 30
per
Kiran Shah
Kiran Shah, CFO of OKYO Pharma, expressed excitement about the partnership with Leerink Partners, highlighting its strategic importance for the company's financial flexibility and pipeline advancement.
Importance 60 Sentiment 10
subs
B. Riley Financial===B. Riley Securities
B. Riley Financial===B. Riley Securities Inc. was replaced by Leerink Partners LLC as the sales agent for OKYO Pharma's ATM facility, indicating a loss of business for the firm.
Importance 50 Sentiment -10
exch
Nasdaq Capital Market
OKYO Pharma's ordinary shares are listed for trading on the Nasdaq Capital Market, which is the venue for the potential sale of common shares through the ATM program.
Importance 10 Sentiment 0
govactor
United States===United States Securities and Exchange Commission
Sales under OKYO Pharma's ATM program will be made pursuant to a prospectus supplement and accompanying base prospectus filed with the United States===United States Securities and Exchange Commission, ensuring regulatory compliance.
Importance 10 Sentiment 0
Relationships
OKYO Pharma related ↔ Leerink Partners
OKYO Pharma related ↔ B. Riley Financial===B. Riley Securities
Kiran Shah related ↔ OKYO Pharma
United States===United States Securities and Exchange Commission related ↔ OKYO Pharma
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.